Navigation Links
Ohio State and Moffitt form world's largest cancer research collaboration for big data
Date:5/30/2014

TAMPA, Fla., and COLUMBUS, Ohio (May 28, 2014) Two of North America's leading cancer centers, Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), today announced what is likely the largest collaboration of its kind to accelerate discoveries in cancer research.

Named the Oncology Research Information Exchange Network (ORIEN), the new partnership will launch with over 100,000 consented patients who have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level. ORIEN will utilize a single protocol, Total Cancer Care, to create a collaborative, "rapid learning" environment that will share de-identified data to accelerate the development of targeted treatments, allowing researchers and clinicians to more quickly match eligible patients to clinical trials and conduct larger and richer analysis.

National System Long Overdue

Leaders of each cancer center emphasized ORIEN's goal to develop more precise ways to prevent, detect, diagnose, and treat cancers.

"Cancer is a highly complex disease, and potential breakthroughs have been stalled because we've lacked an efficient way to share incremental insights," said Alan F. List, M.D., president and CEO of Moffitt. "Even more frustrating, until today we've had no system to quickly match cancer patients from anywhere in the country with ongoing clinical research with the most potential to help them," he said. "By partnering with The Ohio State University through ORIEN, we've built a cancer research expressway."

"With ORIEN, we're amassing a true national cancer database for the first time," said Michael Caligiuri, M.D., director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital. "The collaboration across academic centers and with health care industry will not only help speed discovery, but will also provide patients with more personalized treatment options and ultimately, lead to better outcomes."

Through data analysis and sharing, ORIEN will provide physicians evidence of the best therapeutic options, including clinical trial treatments, specific to a patient's biological and epidemiological profile, increasing the likelihood of treatment efficacy, speeding response time, and potentially minimizing side effects while improving outcomes.

Patients are followed throughout their lifetime and can play an active role in the study of their cancer and improve care for future generations.

ORIEN builds upon the strengths of its founders' National Cancer Institute-designated comprehensive cancer centers: Moffitt's Total Cancer Care protocol, biorepository and data warehouse of patients' genotypic and phenotypic data, and OSUCCC-James's depth and breadth in translating molecular- and genetic-based discoveries into more effective ways to prevent, detect, treat and ultimately cure cancers. M2Gen, a subsidiary of Moffitt, will serve as ORIEN's operational and commercial provider for support, bringing expertise in data management and informatics.

The ORIEN collaborative will seek partnerships with other leading cancer centers in North America. More information may be found at ORIENcancer.org.

Clinical Trial Matching

ORIEN's approach to clinical trial matching also presents a significant opportunity for pharmaceutical companies to modernize trial recruitment and facilitate adaptive clinical trial design. Through M2Gen, industry researchers will be able to match their targeted drugs to participating patients within ORIEN cancer center members based on their molecular profile, promoting greater trial efficiency and flexibility. Ultimately, researchers will be better equipped to identify potential candidates for their drug trials, leading to better outcomes. ORIEN also creates the ability to accelerate and improve efficiencies of clinical trials and the drug approval process, including post-market surveillance.

"M2Gen will facilitate what we view as the ideal way to conduct cancer research and help patients an approach that promotes collaborative learning at all levels," said William S. Dalton, Ph.D., M.D., president and CEO of M2Gen. "The goal of our joint efforts with Moffitt and OSUCCC-James is to connect patients to the best treatment options, including clinical trials, by accelerating the discovery and delivery of personalized medicine."


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Radiation for prostate cancer linked to secondary cancers, study finds
2. Study affirms value of epigenetic test for markers of prostate cancer
3. Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
4. Phase III clinical trial shows image fusion-guided biopsy significantly improves accuracy of prostate
5. Prolaris® test predicts mortality risk in prostate cancer biopsy study
6. Robot-assisted prostate cancer surgery as safe but more expensive as open surgery in older men
7. Low risk prostate cancer not always low risk
8. MicroRNA that could be used to suppress prostate cancer progression found
9. Identified 2 new genes involved in the more aggressive prostate cancer
10. Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment
11. Two genes together drive aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has ... camp held at Oregon State University this summer. Employing world-class rugby figures, including former ... all skill levels with training on key fundamentals, match play, fitness and more. , ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ) ... for global clients of Coupa ( Coupa Software ) and other Cloud software, ... a key component in the suite of innovative implementation services offered by Bluvault. ...
(Date:5/6/2016)... ... 2016 , ... Fat-Freezing, which is what today’s popular technology ... most popular among body sculpting options, according to a new survey of dermatologic ... Richard Buckley, medical director of MilfordMD Cosmetic Dermatology Surgery & Laser Center. Dr. ...
(Date:5/6/2016)... DC (PRWEB) , ... May 06, 2016 , ... Online ... sizes and are changing the game for traditional brokers and health plans. “ The ... upcoming May 17 webinar from Atlantic Information Services, Inc. (AIS), will offer an accurate ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium to the ... will share its insights on managing Customers Engagement at SpeechTek 2016 Event, taking place ... Technology will deliver a Presentation on “5 Customer Engagement Strategies to improve ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... DIEGO , May 6, 2016 Zymo Research ... Urine Kit at the American Urological Association,s Annual Meeting, ... that extracts and isolates total DNA from a large volume ... community at the company,s booth #5151 at the ... Urine Conditioning Buffer ™ (UCB ™ ) ...
(Date:5/6/2016)... India , May 6, 2016 ... Devices Pipeline Assessment, 2016" to its database. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ... includes trial phase, trial status, trial start and ...
(Date:5/6/2016)... , May 6, 2016  Ampronix is excited to announce that we now stock ... 3MOS. First launched last November, the UHD camera was released to the consumer market in ... ... ... The finely crafted GP-UH532 camera is the ...
Breaking Medicine Technology: